PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Milestone product launch for Kelso Pharma

Kelso Pharma has announced its first product launch following the release of its Acepiro product across the UK.

Acepiro, also known as Acetylcysteine, is indicated in adults as a mucolytic agent for the treatment of respiratory tract diseases in which a reduction in bronchial secretion viscosity is required to facilitate expectoration.

The tablets are indicated in adults only and they are being made available to hospital and community prescribers in 20- and 30-day packs. The 30-day packs are consistent with monthly prescribing.

Acepiro is being launched by Stirling Anglian Pharmaceuticals (SAP), which was purchased by Kelso last year, which it hoped would provide a new UK platform for future sales growth throughout the business. The new product complements SAP’s existing portfolio of three medicines: CosmoCol, Stirlescent and theiCal-D3.

Mark Inker, Managing Director UK at Kelso Pharma, explained: “The launch of Acepiro is a significant milestone for Kelso Pharma and for SAP as we pursue our vision to bring value-added medicines to the NHS and healthcare systems across Europe. The SAP team is sharply focused on making Acepiro available to healthcare professionals and to patients who may benefit from its launch.”

Dr Tom Stratford, CEO at Kelso Pharma, concluded: “We’re excited to launch our first new brand through SAP. Acepiro fits closely with Kelso Pharma’s focus on innovative, branded medicines that provide proven benefit to patients while being affordable to the healthcare system.”

“By providing specialty medicines such as Acepiro that are easier for people to take, we aim to improve patient compliance and enhance value to the healthcare system. It’s been a year of significant corporate activity for the Kelso Pharma team since the acquisition of SAP and we anticipate being in a position to announce further developments for the business shortly,” he added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026